Entellus Medical Inc (NASDAQ:ENTL) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 5, 2016
Having a price of $22.12, Entellus Medical Inc (NASDAQ:ENTL) traded -1.16% lower on the day. With the last close up 22.81% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Entellus Medical Inc has recorded a 50-day average of $19.71 and a two hundred day average of $18.01. Volume of trade was up over the average, with 107,488 shares of ENTL changing hands over the typical 40,134
Zacks Investment Research has downgraded Entellus Medical Inc (NASDAQ:ENTL) to Hold in a statement released on Wednesday October 05, 2016.
On 9/29/2015, Piper Jaffray released a statement on Entellus Medical Inc (NASDAQ:ENTL) dropped the target price from $30.00 to $27.00 that suggested an upside of 0.43%.
With a total market value of $0, Entellus Medical Inc has with a one year low of $13.72 and a one year high of $22.57 .
More About Entellus Medical Inc (NASDAQ:ENTL)
Entellus Medical, Inc. is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company's XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company's XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses. Its XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The Company's PathAssist tools provide ENT physicians with a way to confirm sinus location and XprESS device placement. Its FocESS Sinuscopes provide ENT physicians with a solution for endoscopic visualization during a sinus procedure.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.